We previously reported that anti-VEGF lenvatinib effectively recruits GZMK+ CD8 T cells to the tumor site through CXCL9 released from tumor-associated macrophages; however, it also enriched intratumoral stroma by upregulating fibrosis-related pathways [28]. Here, CXCL9 is linked to neoplasm.